Alerts will be sent to your verified email
Verify EmailTORNTPHARM
Torrent Pharma
|
Alkem Laboratories
|
Fortis Healthcare
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
166.0 . | 176.0 . | n/a |
Number of ANDA's Approved By USFDA
|
120.0 . | 145.0 . | n/a |
Domestic Sales Growth - YoY
|
12.9 % | 10.8 % | n/a |
R&D as a % of Total Sales
|
5.0 % | 6.0 % | n/a |
Financials
|
|||
5 yr Average ROE
|
20.0 % | 16.74 % | 2.33 % |
5yr average Equity Multiplier
|
2.34 | 1.42 | 1.73 |
5yr Average Asset Turnover Ratio
|
0.65 | 0.9 | 0.44 |
5yr Avg Net Profit Margin
|
13.21 % | 13.14 % | 2.18 % |
Price to Book
|
14.02 | 5.76 | 4.64 |
P/E
|
58.02 | 33.1 | 59.32 |
5yr Avg Cash Conversion Cycle
|
-189.03 Days | 0.57 Days | -133.71 Days |
Inventory Days
|
54.5 Days | 55.43 Days | 6.17 Days |
Days Receivable
|
41.38 Days | 40.86 Days | 31.7 Days |
Days Payable
|
318.84 Days | 116.85 Days | 220.67 Days |
5yr Average Interest Coverage Ratio
|
5.79 | 24.09 | 3.83 |
5yr Avg ROCE
|
23.72 % | 22.27 % | 4.56 % |
5yr Avg Operating Profit Margin
|
30.68 % | 19.27 % | 14.05 % |
5 yr average Debt to Equity
|
0.83 | 0.22 | 0.19 |
5yr CAGR Net Profit
|
10.08 % | 5.29 % | n/a |
5yr Average Return on Assets
|
8.58 % | 11.73 % | 1.32 % |
Shareholdings
|
|||
Promoter Holding
|
71.25 % | 56.74 % | 31.17 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
Change in Promoter Holding (3 Yrs)
|
0.0 | -3.42 % | 0.0 |
Change in Mutual Fund Holding (3 Yrs)
|
-2.01 % | 5.03 % | 14.26 % |
Torrent Pharma
|
Alkem Laboratories
|
Fortis Healthcare
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|